Table 2.
Clinical characteristics of the validation cohort
| Clinical characteristics | Good outcome group | Poor outcome group | p value |
|---|---|---|---|
| n | 90 | 91 | |
| Age (years) | |||
| Median | 37 | 35 | 0.35 |
| Range | 26–40 | 18–40 | |
| Relapse (years) | |||
| Median | 9.2 | 1.0 | < 0.0001 |
| Range | 5.0–11.2 | 0.3–2.0 | |
| BMI (kg/m2)* | |||
| Mean | 23.3 | 23.2 | 0.84 |
| SD | 2.1 | 2.3 | |
| Histology | |||
| Invasive ductal carcinoma | 83 | 83 | |
| Invasive lobular carcinoma | 6 | 7 | |
| Unknown | 1 | 1 | |
| Grade 1 | 2 | 1 | |
| Grade 2 | 30 | 16 | |
| Grade 3 | 57 | 73 | |
| Unknown | 1 | 1 | |
| Lymph node status | |||
| Negative | 45 | 26 | 0.001 |
| Positive | 45 | 65 | |
| Undetermined | 0 | 0 | |
| ER status | |||
| Positive | 59 | 41 | 0.003 |
| Negative | 31 | 50 | |
| Unknown | 0 | 0 | |
| PR status | |||
| Positive | 42 | 24 | 0.001 |
| Negative | 32 | 52 | |
| Unknown | 16 | 15 | |
| HER2 receptor status | |||
| Positive | 24 | 35 | 0.47 |
| Negative | 49 | 49 | |
| Unknown | 17 | 7 | |
| Triple-negative tumours | 17 | 22 | |
| Resection margin | |||
| R0 resection | 67 | 67 | |
| R1 resection | 7 | 12 | |
| Unknown | 16 | 12 | |
| Chemotherapy | |||
| FEC | 27 | 28 | |
| ECMF | 22 | 18 | |
| FEC + docetaxel | 5 | 14 | |
| AC | 5 | 5 | |
| EC + paclitaxel | 5 | 4 | |
| EC + paclitaxel + gemcitabine | 2 | 4 | |
| EC | 5 | 1 | |
| Null | 10 | 2 | |
| Other | 9 | 15 | |
A adriamycin, BI body mass index, C cyclophosphamide, E epirubicin, ER oestrogen receptor, F 5-fluorouracil, HER2 human epidermal growth factor receptor 2, M methotrexate, PR progesterone receptor, SD standard deviation
*p = 0.13 between groups (unpaired t test)